HaleonFRA:H6D -0.59%76 EV-to-FCF is 17.77 as of Jul. 11, 2026, which is 21% below its 10-year median of 22.52. GuruFocus rates FRA:H6D with a GF Score™ of 76/100 and a GF Value™ of €8.54 (Fairly Valued). The stock has 3 warning signs investors should review. Among 562 Drug Manufacturers companies, Haleon ranks better than 58.36% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Haleon's Enterprise Value is €45,657 Mil.
Haleon's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €2,569 Mil. Therefore, Haleon's EV-to-FCF for today is 17.77.
The historical rank and industry rank for Haleon's EV-to-FCF or its related term are showing as below:
FRA:H6D'
s EV-to-FCF Range Over the Past 10 Years
Min: 16.78 Med: 22.52 Max: 29.3
Current: 17.61
During the past 7 years, the highest EV-to-FCF of Haleon was 29.30. The lowest was 16.78. And the median was 22.52.
FRA:H6D's EV-to-FCF is ranked better than 58.36% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.765
vs FRA:H6D: 17.61
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-11), Haleon's stock price is €8.40.
Haleon's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.429. Therefore, Haleon's PE Ratio (TTM) for today is 19.58.
Haleon (FRA:H6D) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Haleon's share price for today is €8.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Haleon's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.429.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Haleon EV-to-FCF Related Terms
Haleon EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Haleon's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleon EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haleon's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Haleon's EV-to-FCF falls into.
Haleon's current Enterprise Value is €45,657 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Haleon's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €2,569 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haleon (FRA:H6D) has a EV-to-FCF of 17.77 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Haleon and its competitors. This is 21% below median its historical median of 22.52. Over the past decade, Haleon's EV-to-FCF has ranged from 16.78 to 29.30. According to the industry distribution chart, Haleon ranks #234 out of 562 companies in the Drug Manufacturers industry, placing it in the top 41.6%.
Is Haleon's EV-to-FCF too high?
Haleon's current EV-to-FCF of 17.77 is 21% below median its 10-year median of 22.52. Over the past 10 years, this metric has ranged from a low of 16.78 to a high of 29.30. The Drug Manufacturers industry median EV-to-FCF is 20.77. Haleon's value of 17.77 is 14.4% below this industry median. Based on the distribution chart, Haleon ranks #234 out of 562 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Haleon has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Haleon's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Haleon ranks #234 out of 562 companies for EV-to-FCF. This puts Haleon in the upper half of its industry. The industry median EV-to-FCF is 20.77. Haleon's value of 17.77 is 14.4% below this benchmark. Historically, Haleon's own EV-to-FCF has ranged from 16.78 to 29.30 over the past decade. While the company's 10-year median is 22.52 vs. the industry median of 20.77, Haleon has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.77, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haleon's current EV-to-FCF of 17.77 is 14.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Haleon and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haleon's current EV-to-FCF is 17.77, which is 21% below median its own 10-year median of 22.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleon stock overvalued right now?
Based on GuruFocus' analysis, Haleon (FRA:H6D) is currently considered Fairly Valued. The stock's GF Value™ is €8.54, compared to a current price of €8.40 — trading 1.6% below its estimated fair value. The current EV-to-FCF is 17.77, which is 21% below median its 10-year median of 22.52 and 14.4% below the Drug Manufacturers industry median of 20.77. Haleon's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Haleon (FRA:H6D), the current EV-to-FCF is 17.77 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleon (FRA:H6D) Overvalued in 2026?
Based on GuruFocus' analysis, Haleon stock appears to be undervalued.
The current stock price of €8.40 is trading 1.6% below its estimated GF Value™ of €8.54.
GuruFocus considers Haleon to be Fairly Valued.
Key valuation signals for FRA:H6D:
EV-to-FCF: 17.77 (21% below median its 10-year median of 22.52)
GF Value™: €8.54 vs. price of €8.40 (1.6% below fair value)
Industry Position: 14.4% below the Drug Manufacturers median (#234 of 562)
No single metric tells the full story. See the FRA:H6D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
76GF Score
Get the complete analysis for FRA:H6D
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:H6D has been successfully added to your 
